209 related articles for article (PubMed ID: 35115362)
1. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Weidhaas J; Marco N; Scheffler AW; Kalbasi A; Wilenius K; Rietdorf E; Gill J; Heilig M; Desler C; Chin RK; Kaprealian T; McCloskey S; Raldow A; Raja NP; Kesari S; Carrillo J; Drakaki A; Scholz M; Telesca D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115362
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Tan Q; Dai L; Wang Y; Liu S; Liang T; Luo R; Wang S; Lou N; Chen H; Zhou Y; Zhong Q; Yang J; Xing P; Hu X; Liu Y; Zhou S; Yao J; Wu D; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2022 Jul; 71(7):1681-1691. PubMed ID: 34817638
[TBL] [Abstract][Full Text] [Related]
3. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
Front Immunol; 2022; 13():862084. PubMed ID: 35493449
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
5. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
6. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
7. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
[TBL] [Abstract][Full Text] [Related]
8. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
9. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
Gault A; Anderson AE; Plummer R; Stewart C; Pratt AG; Rajan N
Br J Dermatol; 2021 Aug; 185(2):263-271. PubMed ID: 33393076
[TBL] [Abstract][Full Text] [Related]
11. Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer.
Li J; Liu M; Zhang X; Ji L; Yang T; Zhao Y; Wang Z; Liang F; Dai L
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4465-4475. PubMed ID: 36127483
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials.
Reuss JE; Stern D; Foster JC; Ramaswami R; Lurain K; Chen HX; Streicher H; Kem R; Little RF; Sharon E
JAMA Netw Open; 2020 Dec; 3(12):e2027110. PubMed ID: 33258905
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
[TBL] [Abstract][Full Text] [Related]
14. The importance of exosomal PDL1 in tumour immune evasion.
Daassi D; Mahoney KM; Freeman GJ
Nat Rev Immunol; 2020 Apr; 20(4):209-215. PubMed ID: 31965064
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart.
Korste S; Settelmeier S; Michel L; Odersky A; Stock P; Reyes F; Haj-Yehia E; Anker MS; Grüneboom A; Hendgen-Cotta UB; Rassaf T; Totzeck M
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047026
[TBL] [Abstract][Full Text] [Related]
16. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
[TBL] [Abstract][Full Text] [Related]
17. Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy.
Luo K; Liu S; Shen X; Xu J; Shi C; Chao Y; Wen Z; Zhang K; Wang R; Liu B; Jiang Y
Front Cell Dev Biol; 2022; 10():1003656. PubMed ID: 36467413
[No Abstract] [Full Text] [Related]
18. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
20. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
Front Immunol; 2018; 9():1613. PubMed ID: 30123214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]